100 Cambridgepark Drive, Suite 101

Cambridge, MA 02140

March 16, 2022


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn:    Michael Davis
Re:    Vor Biopharma Inc.
   Registration Statement on Form S-3 (File No. 333-263541)

Request for Acceleration of Effective Date


Acceleration Request

Requested Date:         March 18, 2022

Requested Time:         4:00 p.m. Eastern Time

Mr. Davis:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-263541) (theRegistration Statement”) to become effective on March 18, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Richard Segal of Cooley LLP, counsel to the Registrant, at (617) 937-2332.

[Signature page follows]

Very truly yours,

Vor Biopharma Inc.



/s/ Robert Ang


Robert Ang


Chief Executive Officer and Director



   Robert Ang, Vor Biopharma Inc.
Anthony Joyce, Vor Biopharma Inc.

Richard Segal, Cooley LLP

Daniel I. Goldberg, Cooley LLP